Page last updated: 2024-11-13
epi-isozizaene
Description
epi-isozizaene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
Synonyms (11)
Synonym |
(3s,3ar,6s)-3,7,7,8-tetramethyl-2,3,4,5,6,7-hexahydro-1h-3a,6-methanoazulene |
CHEBI:51458 |
(1r,2s,8s)-2,6,7,7-tetramethyltricyclo[6.2.1.0(1,5)]undec-5-ene |
(+)-epi-isozizaene |
EL3 , |
LMPR0103700005 |
CYLSPJUZBPWJGC-PJRDJYAKSA-N |
epi-isozizaene |
2,2,3,7r-tetramethyl-1r,8s-tricyclo-[6.2.1.0(4,8)]undec-3-en |
Q27122614 |
(1r,2s,8s)-2,6,7,7-tetramethyltricyclo[6.2.1.01,5]undec-5-ene |
Drug Classes (1)
Class | Description |
sesquiterpene | A C15 terpene. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 4 (44.44) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |